CA1217429A - Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same - Google Patents

Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same

Info

Publication number: CA1217429A
Authority: CA; Canada
Prior art keywords: caffeine; analgesic; composition according; hydrochloride; inflammatory
Prior art date: 1982-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000432886A

Other languages

English (en)

French (fr)

Inventor

Eugene M. Laska

Abraham Sunshine

Carole E. Siegel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Richardson Vicks Inc

Original Assignee

Richardson Vicks Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-22

Filing date

1983-07-21

Publication date

1987-02-03

1983-07-21 Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc

1987-02-03 Application granted granted Critical

1987-02-03 Publication of CA1217429A publication Critical patent/CA1217429A/en

Status Expired legal-status Critical Current

Links

RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 277
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 138
229960001948 caffeine Drugs 0.000 title claims abstract description 138
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 138
230000000202 analgesic effect Effects 0.000 title claims abstract description 104
239000000203 mixture Substances 0.000 title claims abstract description 82
230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title description 15
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 62
239000004084 narcotic analgesic agent Substances 0.000 claims abstract description 60
230000031990 negative regulation of inflammatory response Effects 0.000 claims abstract description 24
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 16
230000004044 response Effects 0.000 claims description 33
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 22
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 21
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 21
229960002009 naproxen Drugs 0.000 claims description 21
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 20
229960000616 diflunisal Drugs 0.000 claims description 20
229960001419 fenoprofen Drugs 0.000 claims description 20
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 19
239000008194 pharmaceutical composition Substances 0.000 claims description 19
229960001680 ibuprofen Drugs 0.000 claims description 17
229950003779 propiram Drugs 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 14
229960004193 dextropropoxyphene Drugs 0.000 claims description 14
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 13
239000012730 sustained-release form Substances 0.000 claims description 12
WQTLOZFMTGYQDX-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-(1-piperidin-1-ylpropan-2-yl)-n-pyridin-2-ylpropanamide Chemical compound OC(=O)\C=C\C(O)=O.C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 WQTLOZFMTGYQDX-WLHGVMLRSA-N 0.000 claims description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 11
YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 claims description 11
RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims description 10
229960004187 indoprofen Drugs 0.000 claims description 10
BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims description 9
229960003617 oxycodone hydrochloride Drugs 0.000 claims description 9
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 7
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 7
229960004126 codeine Drugs 0.000 claims description 7
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 7
229960000805 nalbuphine Drugs 0.000 claims description 7
229960004004 oxycodone terephthalate Drugs 0.000 claims description 7
229960005301 pentazocine Drugs 0.000 claims description 7
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 7
UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 claims description 6
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 6
229910019142 PO4 Inorganic materials 0.000 claims description 6
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 6
229960001113 butorphanol Drugs 0.000 claims description 6
229960001797 methadone Drugs 0.000 claims description 6
229960005189 methadone hydrochloride Drugs 0.000 claims description 6
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 claims description 6
229960002085 oxycodone Drugs 0.000 claims description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
239000010452 phosphate Substances 0.000 claims description 6
229940065347 propoxyphene hydrochloride Drugs 0.000 claims description 6
BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 claims description 5
DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims description 5
229960003871 codeine sulfate Drugs 0.000 claims description 5
229960002738 hydromorphone hydrochloride Drugs 0.000 claims description 5
RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 claims description 5
229960005157 levorphanol tartrate Drugs 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
MPJUSISYVXABBH-UHFFFAOYSA-N 3-(3-ethyl-1-methylazepan-3-yl)phenol;hydron;chloride Chemical compound Cl.C=1C=CC(O)=CC=1C1(CC)CCCCN(C)C1 MPJUSISYVXABBH-UHFFFAOYSA-N 0.000 claims description 4
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
229960001736 buprenorphine Drugs 0.000 claims description 4
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 4
GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
229960003406 levorphanol Drugs 0.000 claims description 4
229960004473 meptazinol hydrochloride Drugs 0.000 claims description 4
OQGYMIIFOSJQSF-DTOXXUQYSA-N pentazocine hcl Chemical compound Cl.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 OQGYMIIFOSJQSF-DTOXXUQYSA-N 0.000 claims description 4
229960003809 pentazocine hydrochloride Drugs 0.000 claims description 4
229960000482 pethidine Drugs 0.000 claims description 4
ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims description 4
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims description 4
NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 claims description 3
229960001590 butorphanol tartrate Drugs 0.000 claims description 3
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 3
229960001410 hydromorphone Drugs 0.000 claims description 3
229940051129 meperidine hydrochloride Drugs 0.000 claims description 3
229960000365 meptazinol Drugs 0.000 claims description 3
JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims description 3
229960001513 nalbuphine hydrochloride Drugs 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 2
235000021317 phosphate Nutrition 0.000 claims 1
WFPVBPZXBFDFDL-UHFFFAOYSA-N tert-butyl-dimethyl-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indol-1-yl]silane Chemical compound C12=CC=CC=C2N([Si](C)(C)C(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 WFPVBPZXBFDFDL-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 46
229940079593 drug Drugs 0.000 abstract description 45
239000000730 antalgic agent Substances 0.000 abstract description 41
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 31
208000002193 Pain Diseases 0.000 description 27
230000036592 analgesia Effects 0.000 description 27
230000036407 pain Effects 0.000 description 27
230000003533 narcotic effect Effects 0.000 description 26
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 22
241000282412 Homo Species 0.000 description 20
229960001138 acetylsalicylic acid Drugs 0.000 description 19
229940035676 analgesics Drugs 0.000 description 19
238000011282 treatment Methods 0.000 description 17
229960005489 paracetamol Drugs 0.000 description 15
230000000694 effects Effects 0.000 description 14
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 14
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 14
239000005557 antagonist Substances 0.000 description 12
229960002702 piroxicam Drugs 0.000 description 12
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 11
229960000991 ketoprofen Drugs 0.000 description 11
150000001875 compounds Chemical class 0.000 description 10
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
229960003464 mefenamic acid Drugs 0.000 description 10
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 9
239000000556 agonist Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000002671 adjuvant Substances 0.000 description 8
229960001395 fenbufen Drugs 0.000 description 8
ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 8
229960002390 flurbiprofen Drugs 0.000 description 8
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 8
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 8
229960000894 sulindac Drugs 0.000 description 8
239000002260 anti-inflammatory agent Substances 0.000 description 7
229940121363 anti-inflammatory agent Drugs 0.000 description 7
229960003893 phenacetin Drugs 0.000 description 7
ZJXLSCXDGPDZOL-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate;dihydrate Chemical compound O.O.[Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZJXLSCXDGPDZOL-UHFFFAOYSA-M 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 6
238000002483 medication Methods 0.000 description 6
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
239000004081 narcotic agent Substances 0.000 description 6
201000008482 osteoarthritis Diseases 0.000 description 6
150000005599 propionic acid derivatives Chemical class 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
229960003516 zomepirac sodium Drugs 0.000 description 6
ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 5
206010019233 Headaches Diseases 0.000 description 5
150000001242 acetic acid derivatives Chemical class 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 5
ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 5
-1 fenbu~en Chemical compound 0.000 description 5
231100000869 headache Toxicity 0.000 description 5
229960000905 indomethacin Drugs 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
125000000896 monocarboxylic acid group Chemical group 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
BTEYIHUKHHAVAN-KDKWOIFOSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BTEYIHUKHHAVAN-KDKWOIFOSA-N 0.000 description 4
PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 4
206010058019 Cancer Pain Diseases 0.000 description 4
206010012335 Dependence Diseases 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229960004415 codeine phosphate Drugs 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 4
239000003887 narcotic antagonist Substances 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
239000000126 substance Substances 0.000 description 4
229960002044 tolmetin sodium Drugs 0.000 description 4
XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
239000002221 antipyretic Substances 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
229960001889 buprenorphine hydrochloride Drugs 0.000 description 3
UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
229950007979 flufenisal Drugs 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
239000012729 immediate-release (IR) formulation Substances 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229960003803 meclofenamic acid Drugs 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
229960005181 morphine Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
238000012552 review Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
229960001017 tolmetin Drugs 0.000 description 3
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 3
TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 2
PITMOJXAHYPVLG-UHFFFAOYSA-N 2-acetyloxybenzoic acid;n-(4-ethoxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=C(NC(C)=O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C PITMOJXAHYPVLG-UHFFFAOYSA-N 0.000 description 2
SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229940011054 acetaminophen / caffeine Drugs 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
230000003356 anti-rheumatic effect Effects 0.000 description 2
239000003435 antirheumatic agent Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 2
229950005608 bucloxic acid Drugs 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229940065410 feldene Drugs 0.000 description 2
229960004369 flufenamic acid Drugs 0.000 description 2
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
229950001284 fluprofen Drugs 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
229950009183 ibufenac Drugs 0.000 description 2
CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229950002252 isoxicam Drugs 0.000 description 2
YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
229950005175 sudoxicam Drugs 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
229940066690 talwin Drugs 0.000 description 2
239000000052 vinegar Substances 0.000 description 2
235000021419 vinegar Nutrition 0.000 description 2
230000036642 wellbeing Effects 0.000 description 2
GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 description 1
PMSFFTIMOXXPBU-YSGAVMCASA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;2-acetyloxybenzoic acid;n Chemical compound Cl.OC(=O)C1=CC=C(C(O)=O)C=C1.CCOC1=CC=C(NC(C)=O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C PMSFFTIMOXXPBU-YSGAVMCASA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 1
DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 1
RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
PVNIYDCDHSFJTK-UHFFFAOYSA-N 2h-1,2-benzothiazin-4-ol Chemical compound C1=CC=C2C(O)=CNSC2=C1 PVNIYDCDHSFJTK-UHFFFAOYSA-N 0.000 description 1
UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000206575 Chondrus crispus Species 0.000 description 1
OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
QZXATCCPQKOEIH-UHFFFAOYSA-N Florasulam Chemical compound N=1N2C(OC)=NC=C(F)C2=NC=1S(=O)(=O)NC1=C(F)C=CC=C1F QZXATCCPQKOEIH-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
241000577218 Phenes Species 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000008548 Tension-Type Headache Diseases 0.000 description 1
206010046823 Uterine spasm Diseases 0.000 description 1
241000282485 Vulpes vulpes Species 0.000 description 1
229960004892 acemetacin Drugs 0.000 description 1
FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
229940086216 acetaminophen 150 mg Drugs 0.000 description 1
229940107186 acetaminophen 162.5 mg Drugs 0.000 description 1
229940032156 acetaminophen 260 mg Drugs 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229960005142 alclofenac Drugs 0.000 description 1
ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
230000036626 alertness Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229960004663 alminoprofen Drugs 0.000 description 1
FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229940059275 anacin Drugs 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940078194 aspirin 210 mg Drugs 0.000 description 1
229940098003 aspirin 325 mg Drugs 0.000 description 1
229940032153 aspirin 520 mg Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960005430 benoxaprofen Drugs 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
229940085890 caffeine 30 mg Drugs 0.000 description 1
229940085881 caffeine 32.5 mg Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
229960003184 carprofen Drugs 0.000 description 1
IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000003727 cerebral blood flow Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229950010886 clidanac Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940080861 demerol Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940072701 dolobid Drugs 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229940085392 excedrin Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
229950006236 fenclofenac Drugs 0.000 description 1
IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
229960002679 fentiazac Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
229950010931 furofenac Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229950011455 isoxepac Drugs 0.000 description 1
QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
230000009191 jumping Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229950006616 miroprofen Drugs 0.000 description 1
OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
235000013379 molasses Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
229960004715 morphine sulfate Drugs 0.000 description 1
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
230000001095 motoneuron effect Effects 0.000 description 1
229940072709 motrin Drugs 0.000 description 1
208000017445 musculoskeletal system disease Diseases 0.000 description 1
229960000938 nalorphine Drugs 0.000 description 1
229940090008 naprosyn Drugs 0.000 description 1
229960000916 niflumic acid Drugs 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960000851 pirprofen Drugs 0.000 description 1
PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229940072710 ponstel Drugs 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
238000004904 shortening Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
238000002693 spinal anesthesia Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229960004492 suprofen Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229950002345 tiopinac Drugs 0.000 description 1
229950006150 tioxaprofen Drugs 0.000 description 1
229960002905 tolfenamic acid Drugs 0.000 description 1
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000006442 vascular tone Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
229950007802 zidometacin Drugs 0.000 description 1
229960003414 zomepirac Drugs 0.000 description 1
ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

CA000432886A 1982-07-22 1983-07-21 Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same Expired CA1217429A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40059782A	1982-07-22	1982-07-22
US400,597		1982-07-22

Publications (1)

Publication Number	Publication Date
CA1217429A true CA1217429A (en)	1987-02-03

Family

ID=23584242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000432886A Expired CA1217429A (en)	1982-07-22	1983-07-21	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same

Country Status (15)

Country	Link
JP (3)	JPS59501460A (de)
AT (2)	AT389226B (de)
AU (1)	AU558485B2 (de)
BE (1)	BE897356A (de)
CA (1)	CA1217429A (de)
CH (1)	CH659391A5 (de)
DE (1)	DE3390116C2 (de)
FR (1)	FR2530469A1 (de)
GB (1)	GB2134786B (de)
IE (1)	IE55367B1 (de)
IT (1)	IT1206502B (de)
NL (1)	NL191432C (de)
SE (1)	SE466481B (de)
WO (1)	WO1984000488A1 (de)
ZA (2)	ZA835324B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4559343A (en) *	1982-09-07	1985-12-17	Alcon Laboratories, Inc.	Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US4567183A (en) *	1983-03-11	1986-01-28	Analgesic Associates	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) *	1983-10-11	1985-12-10	Richardson-Vicks, Inc.	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
CH664085A5 (de) *	1985-02-08	1988-02-15	Ciba Geigy Ag	Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung.
CH669523A5 (de) *	1986-06-25	1989-03-31	Mepha Ag
GB8626098D0 (en) *	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
US20040115290A1 (en)	2001-06-20	2004-06-17	Tripp Matthew L.	Modulation of inflammation by hops fractions and derivatives
KR20030048026A (ko)	2001-07-06	2003-06-18	펜웨스트 파머슈티칼즈 컴파니	옥시모르폰의 서방형 제제
CN1610551A (zh)	2001-07-06	2005-04-27	恩德制药公司	用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
US8329216B2 (en)	2001-07-06	2012-12-11	Endo Pharmaceuticals Inc.	Oxymorphone controlled release formulations
US8158160B2 (en)	2001-11-13	2012-04-17	Eric Hauser Kuhrts	Anti-inflammatory cyclooxygenase inhibitors
US7914831B2 (en) *	2004-02-27	2011-03-29	Metaproteomics, Llc	Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
JP2006282644A (ja) *	2005-04-05	2006-10-19	Idemitsu Kosan Co Ltd	疲労回復剤
TW201247195A (en) *	2011-04-28	2012-12-01	Kowa Co	Stable pharmaceutical composition
JP7523879B2 (ja) *	2016-10-31	2024-07-29	エスエス製薬株式会社	医薬組成物
JP2021054728A (ja) *	2019-09-27	2021-04-08	興和株式会社	医薬品
JP6811453B1 (ja) *	2020-06-24	2021-01-13	医療法人すぎやま内科	経皮吸収用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3439094A (en) *	1967-07-20	1969-04-15	Warner Lambert Pharmaceutical	Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol
JPS5423132A (en) *	1977-07-19	1979-02-21	Dai Ichi Seiyaku Co Ltd	Analgesic composition
JPS54154416A (en) *	1978-05-26	1979-12-05	Tdk Electronics Co Ltd	High dielectric constant porcelain composition
US4234601A (en) *	1978-12-18	1980-11-18	Mcneilab, Inc.	Analgesic potentiation
US4237140A (en) *	1979-05-18	1980-12-02	E. I. Du Pont De Nemours And Company	Analgesic mixture of nalbuphine and acetaminophen
US4315936A (en) *	1979-12-17	1982-02-16	Ortho Pharmaceutical Corporation	Analgesic composition
JPS56154416A (en) *	1980-04-30	1981-11-30	Kaken Pharmaceut Co Ltd	Antipyretic analgesic composition
US4322427A (en) *	1981-04-16	1982-03-30	Bristol-Myers Company	Analgetic compositions and methods of use

1983
- 1983-07-21 ZA ZA835324A patent/ZA835324B/xx unknown
- 1983-07-21 IT IT8322173A patent/IT1206502B/it active
- 1983-07-21 CH CH1546/84A patent/CH659391A5/de not_active IP Right Cessation
- 1983-07-21 IE IE1715/83A patent/IE55367B1/en not_active IP Right Cessation
- 1983-07-21 CA CA000432886A patent/CA1217429A/en not_active Expired
- 1983-07-21 DE DE3390116T patent/DE3390116C2/de not_active Expired - Lifetime
- 1983-07-21 WO PCT/US1983/001121 patent/WO1984000488A1/en not_active Ceased
- 1983-07-21 FR FR8312109A patent/FR2530469A1/fr active Pending
- 1983-07-21 NL NL8320240A patent/NL191432C/xx not_active IP Right Cessation
- 1983-07-21 AU AU18816/83A patent/AU558485B2/en not_active Expired
- 1983-07-21 JP JP58502781A patent/JPS59501460A/ja active Pending
- 1983-07-21 GB GB08406704A patent/GB2134786B/en not_active Expired
- 1983-07-21 ZA ZA835326A patent/ZA835326B/xx unknown
- 1983-07-21 AT AT0903983A patent/AT389226B/de not_active IP Right Cessation
- 1983-07-21 JP JP58502643A patent/JPS59501459A/ja active Pending
- 1983-07-22 BE BE0/211220A patent/BE897356A/fr unknown
1984
- 1984-03-20 SE SE8401538A patent/SE466481B/sv not_active IP Right Cessation
1988
- 1988-10-05 AT AT0245988A patent/AT389998B/de not_active IP Right Cessation
1994
- 1994-07-18 JP JP6165470A patent/JPH07165583A/ja active Pending

Also Published As

Publication number	Publication date
IE55367B1 (en)	1990-08-29
AT389226B (de)	1989-11-10
BE897356A (fr)	1983-11-14
DE3390116T1 (de)	1985-01-10
JPH07165583A (ja)	1995-06-27
SE8401538L (sv)	1984-03-20
CH659391A5 (de)	1987-01-30
ZA835324B (en)	1984-09-26
ZA835326B (en)	1984-09-26
GB2134786B (en)	1986-05-08
GB8406704D0 (en)	1984-04-18
AU558485B2 (en)	1987-01-29
NL191432B (nl)	1995-03-01
AT389998B (de)	1990-02-26
IE831715L (en)	1984-01-22
AU1881683A (en)	1984-02-23
JPS59501460A (ja)	1984-08-16
JPS59501459A (ja)	1984-08-16
NL191432C (nl)	1995-07-04
ATA245988A (de)	1989-08-15
SE8401538D0 (sv)	1984-03-20
DE3390116C2 (de)	1994-06-16
IT1206502B (it)	1989-04-27
SE466481B (sv)	1992-02-24
GB2134786A (en)	1984-08-22
FR2530469A1 (fr)	1984-01-27
ATA903983A (de)	1989-04-15
WO1984000488A1 (en)	1984-02-16
IT8322173A0 (it)	1983-07-21
NL8320240A (nl)	1984-06-01

Legal Events

Date	Code	Title	Description
2004-02-03	MKEX	Expiry

Publication	Publication Date	Title
EP0114886B1 (de)	1987-09-30	Analgetische und entzündungshemmende zusammensetzungen mit gehalt an kaffein
EP0165308B1 (de)	1989-03-22	Analgesische und antientzündende zusammensetzung, enthaltend xanthine sowie deren verwendungsverfahren
US4567183A (en)	1986-01-28	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
CA1217429A (en)	1987-02-03	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4464376A (en)	1984-08-07	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4656177A (en)	1987-04-07	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4777174A (en)	1988-10-11	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4420483A (en)	1983-12-13	Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
JPH0733331B2 (ja)	1995-04-12	ジフェンヒドラミン類を含んで成る鎮痛および抗炎症組成物
US4587249A (en)	1986-05-06	Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4479956A (en)	1984-10-30	Analgesic compositions comprising propiram and methods of using same
US4599359A (en)	1986-07-08	Hydroxyzine-containing analgesic combinations
US9066950B2 (en)	2015-06-30	Analgesic compositions
JP2009510158A (ja)	2009-03-12	毒物依存症の治療におけるネボグラミンの使用